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Extracellular vesicles (ECVs) are nano-sized vesicles released by all cells in vitro as well as
in vivo.Their role has been implicated mainly in cell–cell communication, but also in disease
biomarkers and more recently in gene delivery.They represent a snapshot of the cell status
at the moment of release and carry bioreactive macromolecules such as nucleic acids, pro-
teins, and lipids. A major limitation in this emerging new ﬁeld is the availability/awareness
of techniques to isolate and properly characterize ECVs.The lack of gold standards makes
comparing different studies very difﬁcult and may potentially hinder some ECVs-speciﬁc
evidence. Characterization of ECVs has also recently seen many advances with the use of
NanoparticleTracking Analysis, ﬂow cytometry, cryo-electron microscopy instruments, and
proteomic technologies. In this review, we discuss the latest developments in translational
technologies involving characterization methods including the facts in their support and the
challenges they face.
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INTRODUCTION
Release of membrane vesicles from the plasma membrane is a
physiological process known to occur in cell cycle activation and
growth without affecting cell viability, and it is a process widely
observed both in vitro and in vivo (Cocucci et al., 2009; Thery
et al., 2009). Extracellular vesicles (ECVs) are generated during
a process called microvascularization either at the plasma mem-
brane (microvesicles) or within endosomal structures (exosomes)
and are comprised of a very heterogeneous population of vesicles
ranging in size and content. Their sizes vary from 20nm in diam-
eter and have been reported up to 900nm,the former comprising
themorehomogenouspopulationofexosomesreleasedfrommul-
tivesicular bodies (MVBs) and the latter,commonly referred to as
MVs, shedding from the plasma membrane (Thery et al., 2009).
Inthismini-review,wewillreferto alltypesof shedvesiclesunder
the common term of ECVs.
Extracellular vesicles’content varies from cell to cell and it has
been shown to reﬂect the content and surface markers of the cell
from which they originate (Skog et al., 2008; Balaj et al., 2011).
These ECVs can also be taken up by neighboring or distant cells
where they release their cargo which can affect the cell’s status
(Cocucci et al., 2009; Camussi et al., 2010). It has been shown
that ECVs can affect immunoresponses,promote tumor invasive-
ness, and metastasis, can confer resistance to drugs, and promote
endothelial cell migration, invasion, and neovascularization act-
ing as carriers of angiogenic stimuli (Lee et al., 2011). Also, since
theycarrycell-speciﬁcsignatures,assessmentofECV’contentmay
be used for diagnostic purposes for early diagnosis of different
cancers, including melanoma, ovarian cancer, kidney, and brain
tumors (Meng et al., 2005; Skog et al., 2008; Lima et al., 2009;
Grange et al.,2011).
Along with physiological signal mediators, ECVs appear as
potential new tools for clinical diagnostics and may be useful in
novel treatment modalities (Lima et al., 2009; Chen et al., 2012).
Several groups are currently looking at ECVs as potential carri-
ers of therapeutic drugs or molecules that would down-regulate
toxic proteins or elicit an anti-tumor immune response when
encapsulating speciﬁc siRNAs or adeno-associated viral vectors
(Alvarez-Erviti et al.,2011; Maguire et al.,2012).
Although this branch of science is growing very fast, it is ham-
pered by limitations in isolation and puriﬁcation technologies as
well as the ability to measure ECV size, concentration, and mol-
ecular content (Momen-Heravi et al., 2012). There is an urgent
need for more reliable and reproducible extracellular vesicle char-
acterization methods so downstream studies in ECVs genomics,
proteomics, and lipidomics can be more standardized and efﬁ-
cient. In this review, we provide a brief overview of some recently
used methods for ECV measurement and characterization for
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sizing and assessing their concentration while emphasizing on
novel cutting-edge technologies.
CHARACTERIZATION OF EXTRACELLULAR VESICLES
Analysis of ECV subpopulations is highly interesting, but has
turned out to be a major challenge due to their small size and
none of the techniques available today can reliably distinguish
them at the single particle level. This analysis would reveal infor-
mation about ECV size, concentration, charge, subcellular origin,
formation process, content, as well as their potential function.
In this mini-review we discuss some new mainstream technolo-
gies including ﬂow cytometry, scattering and ﬂuorescence ﬂow
cytometry, impedance-based ﬂow cytometry, transmission elec-
tronmicroscopy(TEM)andscanningelectronmicroscopy(SEM),
cryo-electron microscopy (Cryo-EM) and single particle analy-
sis,Nanoparticle TrackingAnalysis (NTA),qNano,and large-scale
molecular proﬁling.
FLOW CYTOMETRY
One method for high-throughput multi-parametric analysis and
quantitation of ECVs is ﬂow cytometry. This technology is
designed to scan and sort at a rate of thousands of single cells
or particles per second (van der Pol et al., 2010). Flow cytometry
is widely used to detect origin, size, and morphology of circulat-
ing ECVs (Kim et al., 2002; Hunter et al., 2008; Kesimer et al.,
2009; Mobarrez et al., 2010; Orozco and Lewis, 2010; Zwicker
etal.,2012).Throughhydrodynamicfocusing,thesuspendedcells
ﬂow through a compressed chamber to the interrogation point,
where the sample encounters the laser. The emitted scatter and
ﬂuorescence is then captured and measured by detectors facing
forward and perpendicular to the laser. The intensity of detected
lightisreportedasforwardlightscatter(FLS)andsidelightscatter
(SLS). The quantity of light scattered forward is proportional to
the diameter while SLS denotes morphology and inner anatomy
of ECVs (Kim et al.,2002;van der Pol et al.,2010). In tandem,ﬂu-
orescent light emitted from labeled ECVs travels perpendicular to
the laser, as in SLS, and optics guide the wavelengths to detectors
that record the intensities. Compatible dyes with discrete emis-
sion peaks can be used to detect multiple ﬂuorescences from a
single laser. Filters provide the necessary parameters to capture
the appropriate range of emission peaks enabling the identiﬁ-
cation of heterogeneous populations. In an effort to guide and
control data collection, ﬂow cytometry employs automated and
user conﬁgured thresholds which set points of reference for FLS
that must be surpassed for data collection. It appears in the future
byreducingﬂowchamberdimensions,optimizingtheﬂowcham-
ber geometry, reducing the ﬂow velocity, the next generation of
ﬂow cytometry instruments will be capable of measuring ECVs
with high sensitivity.
SCATTERING AND FLUORESCENCE FLOW CYTOMETRY
Scattering ﬂow cytometry requires bead calibration with poly-
styrene/latex microspheres of known size and count, to permit
quantitation and delineation of heterogeneous ECVs. The detec-
tion limit is greater and/or equal to 300nm and as such, scatter
detectionaloneisaninefﬁcientmethodforanalyzingsmallervesi-
cles (Hein et al., 2008). Fluorescence ﬂow cytometry is more sen-
sitive due toemitted ﬂuorescence intensity beinghigher than light
scatterintensityfortheMPsizerangeof lessthan300nm(vander
Poletal.,2010).Fluorescence-activatedcellsorting(FACS)enables
ECVs to be characterized on the basis of the spectral properties of
the ﬂuorescence signal enabling morphological classiﬁcation and
speciﬁc sorting (Perez-Pujol et al., 2007).
ThelimitationofﬂowcytometryisitsabilitytosortsmallECVs
below 130nm. Zwicker et al. (2012) suggest a bead-based gating
strategy to identify the lower sensitivity of size-related forward
scatterforECVmeasurements(Robertetal.,2009).Improvements
in standardization of vesicle measurements have been reported
by Lacroix et al. (2010) on behalf of the International Society of
Thrombosis and Haemostatic (ISTH). Using Megamix beads,this
study determined that instrumentation with wide-angle FLS pro-
duced consistent measurements of vesicles (Chandler et al., 2011;
Yuanaetal.,2011).vanderPoletal.(2012)alsousedtheMegamix
bead gating strategy to standardize the relationship between scat-
ter and ECVs’ diameter. Notably, they concluded ﬂow cytometers
canindeeddetectsmallerECVsintherangeofexosomesbyswarm
detection,thecaptureof smallerECVsgroupedtogetherandchar-
acterized as a single event (van der Pol et al., 2012). Comparison
of newer instruments in Chandler et al. (2011) show the Apogee
A40 calibrated with 0.4mm polystyrene beads for 1.0mm micro
particles (MPs) can detect higher numbers of MPs and platelets
compared to Megamix gating use.
Heterogeneous ECVs stained with ﬂuorescently labeled anti-
bodies can be identiﬁed and sorted by ﬂuorescence ﬂow cytome-
try. Non-speciﬁc binding and unbound dye can impede accurate
analysis of labeled ECVs, especially smaller vesicles like exo-
somes (Hoen et al., 2012). Hoen et al. (2012) reported success-
ful antibody-mediated detection of phenotypically heterogeneous
exosomes using ﬂuorescence threshold triggering. Their labeling
method and optimization of the Becton Dickinson Inﬂux ﬂow
cytometer(BectonDickinson,Brussels,Belgium)eliminatednoise
signals and permitted comparison of vesicle subsets within the
wholevesiclepopulation,aswellasdetectionofﬂuorescentvesicles
down to 100nm in diameter (Hoen et al., 2012). Mobarrez et al.
(2010) found that measuring the intensity of the markers bound
to platelet-derived ECVs and then translating those intensities
to Molecules of Equivalent Soluble Fluorochrome (MESF) val-
uesincreasedreproducibilityandpermittedcomparisonof results
obtainedfromdifferentinstruments.Inaccuraciesandinstrument
variability in measuring the absolute number of particles per vol-
ume unit is eradicated through use of MESF values to generate
a standard curve based on beads with predeﬁned ﬂuorescence
labeling (Mobarrez et al., 2010).
IMPEDANCE-BASED FLOW CYTOMETRY
The displaced solute increases the impedance across the circuit
by generating a voltage spike proportional to the volume of the
ECV. The lower detection limit of impedance-based ﬂow cytom-
etry is 300nm. Note that aperture size indicates or dictates the
instruments sensitivity to ECV size (Jy et al., 2010). Using dif-
ferent channel diameters, two or more impedance-based ﬂow
cytometers are recommended to encompass the submicron range
(van der Pol et al., 2010). Zwicker et al. (2012) used the Cell
Lab Quanta SC (Beckman Coulter) with an aperture diameter of
40mm for optimal sizing, characterization, and concentration of
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ECVs. They afﬁrm impedance-based ECV sizing lower limits are
commonly 2% of the aperture’s diameter (Zwicker et al., 2012).
Impedance-based cytometry enhances the sensitivity in compar-
ison with standard ﬂow cytometers, but the limiting size range
excludes a small fraction of ECVs (<300nm; van der Pol et al.,
2010; Zwicker et al., 2012).
Pre-analysis, some suggestions such as calibration of poly-
styrene beads and optimization of antibody concentrations are
recommended to standardize the analysis (Zwicker et al., 2012).
Thetechnologycannotprovidesourcingbasedonsurfacemarkers,
morphological, or biocompositional data of ECVs unless com-
binedwithﬂuorescenceandscatteringﬂowcytometry(vanderPol
et al., 2010). Limitations in resolution will cause smaller particles
togoundetectedbutnewerinstrumentssuchasGallios(Beckman
Coulter) and BD-Inﬂux (Becton Dickinson) are equipped with
more sensitive detectors that can enable for more accurate dis-
crimination of particle populations down to 100nm in diameter
(Lacroix et al., 2010). Orozco and Lewis found that basing their
thresholdonthenumberofbackground“noise”/eventspersecond
when double ﬁltered (0.2mm) phosphate buffered saline (PBS)
was passed through the Gallios instrument (Beckman Coulter)
was effective (Orozco and Lewis). This assay will probably be fur-
ther explored in the future and may shed light into the ECVs
subpopulation subtypes quantitatively and qualitatively.
TRANSMISSION ELECTRON MICROSCOPY AND SCANNING ELECTRON
MICROSCOPY
There are two types of electron microscopes, the TEM and the
SEM. TEM has similarities to light microscopes, transmitting a
beam of electrons through a thin specimen and then focusing the
electrons to create an image on a screen or on ﬁlm. TEM is the
most commonly used and has the highest resolution. SEM,on the
other hand, scans a ﬁne beam of electrons onto a specimen and
collectstheelectronsscatteredonthesurface.AlthoughSEMreso-
lutionislessthanTEM,itconfersdetailedthree-dimensional(3D)
images of surfaces. Because the wavelength of electrons is more
thanthreeordersof magnitudeshorterthanthewavelengthof vis-
ible light,the resolution of TEM can be lower than 1nm (Pisitkun
et al., 2004; van der Pol et al., 2012). Since TEM is performed in
a vacuum, biomaterials require ﬁxation and dehydration, which
reduces their size and changes their morphology. ECVs usually
appear 20–100nm in size and cup-shaped when visualized by
TEM. Employing immuno-gold labeling could lead to biochemi-
cal information regarding ECVs’ surface (van der Pol et al., 2012;
Figure 1). Although TEM has been used extensively for detection
of ECVs (Baran et al., 2010; Miranda et al., 2010; Waldenstrom
et al., 2012), this method only provides semi-quantitative infor-
mation on ECVs. Furthermore, sample dehydration and vacuum
proceduresrequiredinElectronMicroscopy(EM)mightaffectthe
characteristics of ECVs. The measurement time is in the order of
hours.
CRYO-ELECTRON MICROSCOPY AND SINGLE PARTICLE ANALYSIS
Cryo-electronmicroscopyisaformof EMwheresamplesareana-
lyzed at temperatures below  100˚C and has been successfully
applied to ECV analysis. The advantage of this technique is that
samplesareanalyzedinfrozenconditionswithoutbeingstainedor
FIGURE 1 |Transmission electron microscopy (TEM) characterization of
human serum derived extracellular vesicles (ECVs). (A) ECVs were
negatively stained with 2% uracyl acetate after removing the extra
moisture. Cup-shaped structures, with 30–100nm size were identiﬁed as
being exosome/microvesicles. (B) ECVs isolated from human serum
expressing CD63Transmembrane protein which is believed to be
exosome/microvesicles marker. ECVs were immuno-gold labeled with
rabbit polyclonal Abs against CD63.
ﬁxed. This technique has been used for the study of ECVs isolated
from urine and revealed repetitive “mushroom-shaped” features
on the surface of ECVs (Conde-Vancells et al., 2010).
Usually categorized as one of the techniques of cryo-EM, sin-
gle particleEM reconstructionhas recentlybecome apopular tool
to get the 3D structure of proteins and viruses. This method has
advantages in comparison with X-ray crystallography including
no need to crystallize the proteins and no need for large amounts
of protein samples (in range of microliters; Liu and Wang, 2011).
Despite single particle EM has the ability to map the 3D struc-
ture of samples at 1nm resolution, it works better for more
symmetrical structures. The techniques has the capability of dis-
tinguishing different molecular orientations and digitalizing it.
Employing two-dimensional (2-D) alignment and classiﬁcation
methods, homogenous molecules in the same view are grouped
into their respective classes. In each view, their averages increase
thesignalof themolecule’s2-Dshapes.Afterward,softwareorders
the structures with the proper relative orientation (Euler angles)
and generates the 3D images based on combining 2-D digital-
ized micrographs. Liu andWang (2011) described procuring a 3D
reconstruction of yeast exosome complex using negative staining
www.frontiersin.org September 2012 | Volume 3 | Article 354 | 3Momen-Heravi et al. Methods for characterization of extracellular vesicles
EM and single particle EM. This technique will need to be further
explored in the future of ECV characterization.
NANOPARTICLE TRACKING ANALYSIS
A recently developed technique that allows sizing and counting
of ECVs is the NTA (Dragovic et al., 2011; Figure 2). It utilizes
a laser light scattering microscope, charge-coupled device cam-
era (CCD), and proprietary analytical software. A laser beam hits
the ECVs and their Brownian motion is then determined by a
highly sensitive CCD camera and the mean velocity of each parti-
cle is calculated with image processing software. ECVs from 30 to
1000nm in diameter at a concentration range of 108–109 can be
counted with relatively high sensitivity. The NTA software is then
able to identify and track individual ECVs moving under Brown-
ian motion and relates the movement to a particle size based on
the following formula derived from the Stokes–Einstein Equation
(Filipe et al., 2010):
 
x,y
2 D
2kBT
3rhp!
where kB, is the Boltzmann constant and .x,y/2is the mean-
squared speed of a particle at a temperature T, in a medium of
viscosity !, with a hydrodynamic radius of rh.
The Nanosight technology allows detection of ECV subpopu-
lations by using antibody-mediated ﬂuorescent labels that specif-
ically bind to the antibodies of interest on the surface of ECVs
(Dragovicetal.,2011).Thisfeatureenablesuserstodetect,analyze,
and count only the speciﬁc nanoparticles to which the ﬂuores-
cently labeled antibody are bound, with background non-speciﬁc
particulatesbeingexcludedthroughthe useof appropriateoptical
ﬁlters.
qNANO (IZON)
The qNano is a relatively new technology that allows detection of
a ECVs passing through a nanopore by way of a single-molecule
electrophoresis. Branton et al. (2008) introduced nanopores as a
promisingapproachforstudyingbiophysicsatthesingle-molecule
level. The technology is based on the Coulter principle at the
nano scale, and operates by detecting transient changes in the
ionic current generated by the transport of the target particles
through a size tunable nanopore in a polyurethane membrane
(Garza-Licudine et al.,2010). The qNano instrument consists of a
nanopore formed by needle perforation on a polyurethane mem-
brane that is stretched mechanically to permit real-time manip-
ulation of nanopore size. A transmembrane voltage is generated
andasparticlestravelacrossthenanoporethealteredioniccurrent
is captured. Furthermore,data is presented by particles transitory
blockage of the pore establishing measurable change in the elas-
ticity of the channel. Fixed geometry pores are typically useful for
detecting a limited size range or type of particle. qNano provides
quantitative analysis of particle samples spanning from 70nm to
10mm in diameter and concentrations from 105 to 1012 ml 1.
Furthermore, real-time monitoring of ionic current ﬂow across
the pore at different aperture settings enables one to tune the
detection and discrimination of individual nanoparticles popu-
lations in mixed multimodal suspensions. Despite the individual
FIGURE 2 | Nanoparticle tracking analysis (NTA) of human serum
derived extracellular vesicles (ECVs). (A)The image presents particles
moving under Brownian motion. (B)The NTA software then rapidly
generates a distribution graph on a particle-by-particle basis and a count (in
terms of absolute number concentration) of the vesicles.
particle-by-particle readout,the lower limit of detection for ECVs
isintherangeof 100nm(Figure3).Asthetechnologyevolves,we
believe this aspect will improve over time.
RAMAN SPECTROSCOPY
Raman Spectroscopy is a spectroscopic method, based on inelas-
tic scattering of monochromatic light (mostly laser light). It is
used to study vibrational, rotational, and other low-frequency
transitions in a system (Puppels et al., 1990). Photons inter-
act with molecular vibrations, photons, or other excitations
in the system, leading to a slight up- or down shift of their
energy. The shift in energy provides information about the vibra-
tional transitions in the molecules (Puppels et al., 1990; van
der Pol et al., 2010). Given the makeup of ECVs, their chemi-
cal composition could be distinguished by RS with the advan-
tage that ECVs do not have to be pre-processed or labeled. RS
is a quantitative technique and the signal strength is linearly
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FIGURE 3 | qNano generated data of human serum derived extracellular vesicles (ECVs). Plot depicts particle size diameter vs. percentage (%) of
population.The concentration was reported as 1.410
10 particlesml
 1 with mode of 120nm.
proportional to composition of the ECVs. The measurement time
is in the order of few hours. RS can also be coupled with TEM,
NTA, and dynamic light scattering devices to correlate detailed
biochemical information with the relative size distribution and
morphology.
LARGE-SCALE MOLECULAR PROFILING “OMIC”
TECHNOLOGIES IN COMPOSITIONAL CHARACTERIZATION
OF ECVs
Shedding a nuclear fragments of cellular membrane, ECVs, is
an integral part of physiological homeostasis and communi-
cation of various cells of the organism. Alterations in vesi-
cle concentrations and molecular compositions have been asso-
ciated with diseases and physiological states, indicating their
diagnostic potential (Simak and Gelderman, 2006). Emerging
“omic” approaches for in-depth molecular proﬁling seem attrac-
tive for revealing MV-related diagnostic and prognostic biomark-
ers as well as for understanding biogenesis and signaling of
cells and ECVs. Recent advances in “omic” technologies could
play an important role in order to elucidate the roles of ECVs
studying their molecular composition. Several recent reports
have effectively utilized proteomic, metabolomic, and microarray
proﬁling techniques to address speciﬁc questions through mole-
cular characterization of ECVs isolated from various physiolog-
ical ﬂuids and cell cultures (Mayr et al., 2009; Didangelos et al.,
2012).
Proteomic technologies allows for both unbiased discovery-
driven and targeted large-scale protein proﬁling. Moreover, MV
constituents revealed by proteomics techniques can be used
in antibody-based enrichment, detection, and characterization
by the above discussed methodologies. During the past several
years 2-D gel- and mass spectrometry (MS)-based proteomics
has been successfully applied to MV research, leading to the
identiﬁcation of novel signaling and secreted proteins that may
have important physiological roles (Garcia et al., 2005; Smalley
et al., 2008; Dean et al., 2009; Parguina et al., 2012; Shai et al.,
2012).
The traditional 2-D gel electrophoresis technique utilizes in-
gel isoelectrofocusing followed by SDS polyacrylamide gel elec-
trophoresis to separate individual proteins that can be visu-
alized by ﬂuorescent or visible staining, quantiﬁed by optical
density readouts, digested with proteolytic enzymes, and iden-
tiﬁed by MS-based proteomics. As an example, 2-D gel analy-
sis followed by MS-based protein identiﬁcation demonstrated
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that signiﬁcantly higher levels of phosphatidylserine-bearing
ECVs originated mostly from oxidatively damaged platelets and
RBCs can be successfully linked b-thalassemia/hemoglobin (Eb-
thal/HbE) disorder (Chaichompoo et al., 2012). Another recent
report shows that platelets shed EVCs in different amounts and
of different protein composition depending on the stimulus (Shai
et al., 2012).
The ﬁeld of MS-based proteomics has substantially advanced
over the last decade due to revolutionary changes in technol-
ogy, sample preparation, separation platforms, and bioinformat-
ics. Current proteomic technologies are capable of low attomole
detection and therefore more efﬁcient in analysis of small sample
amounts. The conventional MS-based proteomic proﬁling uses
up-frontsingleormultidimensionalseparationofproteinsorpro-
tein digests followed by on-the-ﬂy structural characterization by
single stage and tandem MS. The most common separation tech-
nique used in proteomic analysis of ECVs prior to liquid phase
chromatography coupled to MS is 1-D SDS gel electrophoresis.
Themainadvantagesof thistechniqueisitssimplicityandrelative
efﬁciency in analysis of hydrophobic and membrane proteins that
are expected to be enriched in ECVs. Also, 1-D PAGE effectively
delipidates lipid-rich ECVs,that can be beneﬁcial for downstream
MS analysis. Rapid progress in high accuracy high resolution MS
enabled reliable quantitative proteomic analysis and proﬁling of
post-translational modiﬁcations. A recent study focused on the
physiological erythrocyte aging process; they applied MS-based
proteomic proﬁling to support a hypothesis stating vesiculation
of damaged and degraded membrane patches of erythrocytes
may serve to postpone the premature removal of functional cells
(Bosman et al., 2012). This study demonstrated a selective accu-
mulation of ubiquitinylated proteins or peptides as well as several
otherpost-translationalmodiﬁcationsinECVsderivedfromaging
RBCsthatcanleadtothesubsequentrecognitionandfastremoval
of ECVs by the immune system (Bosman et al., 2012). MS-based
proﬁling allows one to reliably assess the baseline of intra- and
inter-individualvariabilityinECVcompositionpriortoanyeffort
forbiomarkerdetections(Rubinetal.,2010;Bastos-Amadoretal.,
2012).
New ﬁelds of large-scale metabolomic, lipidomic, and pep-
tide/protein array proﬁling techniques are emerging following the
recent wake of the genomic and proteomic revolutions (Grifﬁths
et al., 2011). These new “omic” technologies are expected to also
be very instrumental in providing complementary information
about structural features of ECVs and in development of novel
diagnostic, prognostic, and therapeutic approaches.
CONCLUSION
In conclusion, a combination of the different methods described
above can provide information on the different characteristics of
ECVs. These methods should be further assessed and validated by
comparing measurement results, so that precise, reliable, and fast
extraction methods and measurements could eventually be trans-
latable from the bench to the clinic. As the area of ECVs shift to
the clinical arena, the characterization step will need to be stan-
dardized to ensure a more precise and sensitive measurement.
This may include combining complementary characterization
methodologies.
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